Filter news stories by category:
- UCLH news
- Charity news
-
Research news
- Governors news
- Red Cell Network news
- HTD news
- Reset filter
-
Research news
-
Research news
11 November 2021
Professor Charles Swanton is one of three innovative cancer investigators to be awarded the prestigious Paul Marks Prize for Cancer Research by the Memorial Sloan Kettering Cancer Center (MSK).
-
Research news
24 August 2021
An antibody treatment trialled at UCLH cuts the risk of developing symptomatic COVID-19 by 77%.
-
Research news
11 August 2021
A national study involving UCLH has deepened understanding of the symptoms, signs and outcomes of patients with the novel condition vaccine-induced immune thrombocytopenia and thrombosis (VITT), associated with the Oxford/AstraZeneca vaccine.
-
Research news
-
Research news
20 July 2021
A clinical trial of a new drug candidate for Alzheimer’s disease which has been developed at UCL in partnership with the pharmaceutical company Eisai has begun at UCLH with participants now being screened.
-
Research news
18 July 2021
A major new consortium led by UCLH and UCL has been awarded £6.8 million by the National Institute of Health Research to conduct the largest clinical study of long COVID over the next two years.
-
Research news
09 July 2021
A record 119 patients have been recruited to the UCLH-led, charitably funded, IPI-GLIO immunotherapy clinical trial for NHS patients recently diagnosed with glioblastoma brain cancer.
-
Research news
02 July 2021
UCLH, UCL and spinout company Odin Vision have used artificial intelligence (AI) to help detect early signs of oesophageal cancer in a global first.
-
Research news
29 June 2021
Two doses of the Oxford-AstraZeneca COVID-19 vaccine induce lower levels of antibodies that are able to recognise and fight the SARS-CoV-2 Delta variant (B.1.617.2) than against other strains, according to laboratory findings from UCLH and the Francis Crick Institute.